Manotti named senior vice president, chief development officer at MSKCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Kenneth Manotti has been named senior vice president and Chief Development Officer at Memorial Sloan Kettering Cancer Center.

Manotti has more than 30 years of fundraising and leadership experience at major institutions, including the University of Pennsylvania, Columbia University, the American University in Cairo, and the University of Chicago. He was senior vice president of University Development and Alumni Relations at New York University.

Manotti’s appointment concludes a national search for new leadership for MSK’s fundraising program, which was led for the past 15 years by Richard Naum as senior vice president for Development and Anne McSweeney as Special Advisor to the President.

Under their direction, the Campaign for MSK surpassed its $3.5 billion goal, providing vital support for innovation and discovery research to transform cancer treatment in New York and around the globe.

At the University of Chicago, where Manotti served as vice president for Alumni Relations and Development from 2011 to 2017, he helped direct a successful $5 billion capital campaign, working collaboratively with university leadership, trustees, and advancement colleagues.

Before that, he served as vice president for Institutional Advancement at the AUC, where he led university-wide development, alumni affairs, and marketing and communications programs in the United States, the Middle East, and Europe. Prior to his work at the AUC, he was associate dean for External Affairs at the University of Pennsylvania’s Wharton School of Business, where he directed the $550 million Wharton Campaign.

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login